These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 18072814)

  • 21. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization.
    Potkin SG; Gharabawi GM; Greenspan AJ; Mahmoud R; Kosik-Gonzalez C; Rupnow MF; Bossie CA; Davidson M; Burtea V; Zhu Y; Trivedi JK
    Schizophr Res; 2006 Jul; 85(1-3):254-65. PubMed ID: 16797162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Managing acute exacerbations of schizophrenia: focus on quetiapine.
    Arango C; Bobes J
    Curr Med Res Opin; 2004 May; 20(5):619-26. PubMed ID: 15140327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quetiapine: efficacy and tolerability in schizophrenia.
    Kasper S; Tauscher J; Heiden A
    Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S405-13. PubMed ID: 11587888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia.
    Möller HJ; Johnson S; Mateva T; Brecher M; Svensson O; Miller F; Meulien D;
    Int Clin Psychopharmacol; 2008 Mar; 23(2):95-105. PubMed ID: 18301124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quetiapine versus typical antipsychotic medications for schizophrenia.
    Suttajit S; Srisurapanont M; Xia J; Suttajit S; Maneeton B; Maneeton N
    Cochrane Database Syst Rev; 2013 May; (5):CD007815. PubMed ID: 23728667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia.
    Copolov DL; Link CG; Kowalcyk B
    Psychol Med; 2000 Jan; 30(1):95-105. PubMed ID: 10722180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia.
    Järbrink K; Kreif N; Benedict A; Locklear J
    Curr Med Res Opin; 2009 Mar; 25(3):709-16. PubMed ID: 19196221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.
    Cutler AJ; Tran-Johnson T; Kalali A; Aström M; Brecher M; Meulien D
    Psychopharmacol Bull; 2010; 43(4):37-69. PubMed ID: 21240151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid dose titration of quetiapine for the treatment of acute schizophrenia and acute mania: a case series.
    Pajonk FG; Schwertner AK; Seelig MA
    J Psychopharmacol; 2006 Jan; 20(1):119-24. PubMed ID: 16204326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid dose escalation with quetiapine: a pilot study.
    Smith MA; McCoy R; Hamer-Maansson J; Brecher M
    J Clin Psychopharmacol; 2005 Aug; 25(4):331-5. PubMed ID: 16012275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focus on quetiapine.
    Green B
    Curr Med Res Opin; 1999; 15(3):145-51. PubMed ID: 10621920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quetiapine for schizophrenia.
    Srisurapanont M; Disayavanish C; Taimkaew K
    Cochrane Database Syst Rev; 2000; (2):CD000967. PubMed ID: 10796560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.
    Lindenmayer JP; Brown D; Liu S; Brecher M; Meulien D
    Psychopharmacol Bull; 2008; 41(3):11-35. PubMed ID: 18779774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quetiapine for schizophrenia.
    Srisurapanont M; Disayavanish C; Taimkaew K
    Cochrane Database Syst Rev; 2000; (3):CD000967. PubMed ID: 10908478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study.
    Mamo DC; Uchida H; Vitcu I; Barsoum P; Gendron A; Goldstein J; Kapur S
    J Clin Psychiatry; 2008 Jan; 69(1):81-6. PubMed ID: 18312041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.